D300 patient experiences following the olfus vipes phase iib epicutaneous immunotherapy trial: a retrospective qualitative study

For children with peanut allergy (PA) and their families, living with the possibility of a potentially life-threatening reaction can decrease health-related quality of life (HRQL). Reducing the risk of reactions due to accidental ingestion through immunotherapy may improve HRQL. In a Phase IIb trial, daily epicutaneous immunotherapy (EPIT) with 250- μg peanut patch (∼1/1000 of 1 peanut kernel) resulted in significant treatment response versus placebo. Objectives of this qualitative, multisite, retrospective study were to assess patients’ HRQL, treatment expectations, and satisfaction.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Food Allergy Source Type: research